Products and Pricing
Please scroll down to view the pricing information for PatientView products and services.
Corporate Reputation of Pharma
The annual Corporate Reputation of Pharma report is based on the feedback of over 2400+ patient groups worldwide. This report provides invaluable insights into how pharma companies are perceived (and ranked) by patient groups and how they can improve.
The complete package is delivered as 22 reports. All reports are available on a global licence, which can be circulated to all of a company’s full-time employees. Two editions are available: (1) all pharma companies that were reviewed (2) results for ‘big pharma’ only
11 geographic areas
- Global
- ANZ
- Canada
- China
- France
- Germany
- Italy
- Japan
- Spain
- UK
- USA
11 therapy areas
- Bleeding Disorders
- Cancer (All Types)
- Cancer (Blood)
- Cancer (Breast)
- Cancer (Lung)
- Cancer (Prostate)
- Diabetes
- Multiple Sclerosis
- Neurology
- Neurodegenerative Disease
- Rare Diseases
Pricing
Purchase of 1st report: £9350
Additional geographical or therapy Area reports: €1650 (per report)
Additional bespoke reports (for example, a combination of therapy areas: €9350 (per report)
Specialist reports. key analytical pointers: £2200 (per report)
PowerPoint deck: £2200 (per report)
Moving Forward
The Moving Forward series of dashboards focuses on the feedback received from patient groups, listing their priorities for pharma, based on the set of ten indicators of corporate reputation.
Delivered as a user-friendly online dashboard, using unbiased and robust data. The dashboard lets you mine, navigate, sort and export what matters most to the patient groups in the target therapy areas and markets of interest to your company.
The data are generated in seconds. There are two versions of Moving Forward: (1) global and therapy-wide data (2) feedback from just your company’s patient-group partners.
Pricing
Feedback from your company’s patient group partners: £24,000 (includes global and therapy-wide dashboard all patient group responses)
Patients In Action
The extensive and granular data in the Patients In Action online dashboard is analysed to identify trends and differences in the relationships between patient groups (of 37 therapy areas) and healthcare systems (of 19 countries). Healthcare companies can therefore fine-tune their strategies to optimise the support they provide their patient group partners.
As part of the Patients in Action repertoire, later in 2026 PatientView is to release findings of a new 2025/2026 study on patient groups involvement with drug pricing regulators, “Patient groups: a seat at the pricing table”. Some 2,000 respondents worlwide answered the survey, with 900 prividing feedback on how they interact with drug pricing regulators.
Pricing
Patients in Action online dashboard + PDF report: £12,000
Patient groups: a seat at the pricing table: £9,500 / data on how your company’s patient-group partners interact with drug-pricing regulators.
Contact PatientView for more information by using the form below: